Immunotoxins Market Size To Reach $243.3 Million By 2030

Immunotoxins Market Growth & Trends

The global immunotoxins market is anticipated to reach USD 243.3 million by 2030 and is anticipated to expand at a CAGR of 8.08% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of cancer and technological advancements are some of the factors anticipated to drive market growth.

Immunotoxins are a class of targeted therapeutics that combine a cytotoxic agent with a targeting moiety, such as an antibody or growth factor. The development of immunotoxins has gained momentum due to their potential effectiveness in treating various cancers and other diseases. Cancer is a growing concern worldwide, with an estimated 20 million new cases and 9.7 million deaths in 2022. Immunotoxins consist of an antibody fragment, or a targeting moiety linked to a toxin, which allows for selective delivery of the toxic agent directly to cancer cells. Moreover, the development and application of immunotoxins have evolved significantly over recent years, leading to various ongoing research initiatives aimed at improving their efficacy, reducing immunogenicity, and expanding their therapeutic applications. Researchers are identifying novel tumor-specific antigens that could serve as targets for new immunotoxin therapies.

The COVID-19 pandemic led to significant disruptions in global supply chains. Manufacturing facilities faced shutdowns or reduced operations due to health regulations and workforce shortages. This situation affected the availability of raw materials and components necessary for producing immunotoxins. Moreover, the pandemic fostered collaboration among pharmaceutical companies, academic institutions, and government entities to accelerate drug development processes, further propelling market growth. 

However, one of the primary challenges associated with immunotoxin therapies is the potential for severe side effects. Patients may experience adverse reactions such as nausea, diarrhea, and fever. For instance, certain toxins like Ricin-based immunotoxins have been associated with severe complications such as capillary leak syndrome or hepatotoxicity. Such risks can lead to clinical trial terminations or regulatory hurdles during drug approval processes, further limiting market growth.

 Request a free sample copy or view report summary: Immunotoxins Market Report

Immunotoxins Market Report Highlights

• Based on product, the Diphtheria Toxin (DT) segment held the largest market share of 43.96% in 2023. DT-based immunotoxins are highly effective in targeting specific cancer cells, making them valuable for treating cancers that are resistant to standard therapies like chemotherapy and radiation. On the other hand, Pseudomonas Exotoxin (PE) is anticipated to grow at a significant CAGR over the forecast period.

• Based on application, in 2023, therapy development segment is anticipated to dominate the market share for the application segment and is anticipated to grow at the fastest CAGR over the forecast period.

• Based on end-use, pharmaceutical & biotechnology companies segment dominated the end use segment with the largest share of 46.40% in 2023 and is anticipated to grow at the fastest CAGR over the forecast period. However, on the other hand, academic institutes is anticipated to grow at a significant CAGR over the forecast period.

• Based on region, North America region dominated the market with a share of 41.41% owing to factors such as strong R&D in biotechnology, medicine, and therapeutics, along with substantial government funding. Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period.

Immunotoxins Market Report Segmentation

Grand View Research has segmented the global immunotoxins market on the basis of product, application, end-use, and region:

Immunotoxins Product Outlook (Revenue, USD Million, 2018 - 2030)

• Diptheria Toxin (DT)

• Anthrax Based Toxins

• Pseudomonas Exotoxin (PE)

• Other Immunotoxins

Immunotoxins Application Outlook (Revenue, USD Million, 2018 - 2030)

• Biomedical Research

• Therapy Development

Immunotoxins End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical & Biotechnology Companies

• CROs & CMOs

• Academic & Research Institutes

Immunotoxins Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Immunotoxins Market

• Creative Biolabs.

• List Biological Labs, Inc.

• The Native Antigen Company

• Bio-Techne.

• Abcam Plc.

• CAYMAN CHEMICAL

• Merck KGaA

• Enzo Life Sciences, Inc

• Santa Cruz Biotechnology, Inc.

• Quadratech Diagnostics Ltd.